Jesse Solomon

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…

Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…

Davis Polk is advising Metalmark Capital in connection with the sale of WorldStrides. Under the terms of the sale and merger agreement, Metalmark and its co-investors have agreed to sell…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk is advising First Data Corporation on the formation of a joint venture with FLEETCOR Technologies Inc. The new joint venture combines the gift card businesses of both companies…